Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 178

Results For "LA"

8967 News Found

Supriya Lifescience signs solar agreement with Enrich Energy
Sustainability | December 22, 2022

Supriya Lifescience signs solar agreement with Enrich Energy

The project will generate and supply green energy to fulfill about 50% present consumption of the company


Indira IVF forays into diagnostic business with ‘Indira Pathlabs’
News | December 21, 2022

Indira IVF forays into diagnostic business with ‘Indira Pathlabs’

Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients


Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
People | December 20, 2022

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund


Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
News | December 20, 2022

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years


Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
Drug Approval | December 20, 2022

Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer

This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting


SRL Diagnostics launches laboratory in Panchkula
News | December 19, 2022

SRL Diagnostics launches laboratory in Panchkula

The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology


Takeda launches CINRYZE in India for hereditary angioedema patients
News | December 15, 2022

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.


Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise
News | December 15, 2022

Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise

The company will submit an action plan on the observations and will engage with US FDA for next steps.


De Nora and Aclarity sign agreement to deploy PFAS destroying technology
News | December 15, 2022

De Nora and Aclarity sign agreement to deploy PFAS destroying technology

The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally